These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 998329)

  • 1. Excretion and organ distribution of the cytostatic preparation Ledakrin (preparation C-283) in rat.
    Jerzykowski T; Szalsza-Kuśnierczyk M; Chalupka G; Chorazy M
    Acta Med Pol; 1976; 17(3):169-74. PubMed ID: 998329
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the mechanism of antitumour activity of Ledakrin.
    Konopa J; Chotkowska E; Koldej K; Matuszkiewicz A; Pawlak JW; Woynarowski JM
    Mater Med Pol; 1976; 8(3):258-65. PubMed ID: 1011867
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro binding of metabolically activated [14C]-ledakrin, or 1-nitro-9-14C-(3'-dimethylamino-N-propylamino) acridine, a new antitumor and DNA cross-linking agent, to macromolecules of subcellular fractions isolated from rat liver and HeLa cells.
    Pawlak JW; Konopa J
    Biochem Pharmacol; 1979 Dec; 28(23):3391-402. PubMed ID: 43732
    [No Abstract]   [Full Text] [Related]  

  • 4. Antineoplastic activity of C-283 preparation (Ledakrin) in model experiments.
    Radzikowski C
    Mater Med Pol; 1976; 8(3):345-9. PubMed ID: 1034860
    [No Abstract]   [Full Text] [Related]  

  • 5. Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro.
    Gorlewska K; Mazerska Z; Sowiński P; Konopa J
    Chem Res Toxicol; 2001 Jan; 14(1):1-10. PubMed ID: 11170502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 32P-post-labeling analysis of DNA adduct formation by antitumor drug nitracrine (Ledakrin) and other nitroacridines in different biological systems.
    Bartoszek A; Konopa J
    Biochem Pharmacol; 1989 Apr; 38(8):1301-12. PubMed ID: 2706021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent binding of 1-nitro-9-(3-dimethyl-n-propylamino) acridine, a new antitumor drug, to DNA of Ehrlich ascites tumor cells in vivo.
    Konopa J; Koldej K; Pawlak JW
    Chem Biol Interact; 1976 Apr; 13(1):99-103. PubMed ID: 1260948
    [No Abstract]   [Full Text] [Related]  

  • 8. The mode of action of cytotoxic and antitumor 1-nitroacridines. II. In vivo enzyme-mediated covalent binding of a 1-nitroacridine derivative, Ledakrin or Nitracrine, with dna and other macromolecules of mammalian or bacterial cells.
    Pawlak JW; Pawlak K; Konopa J
    Chem Biol Interact; 1983 Feb; 43(2):151-73. PubMed ID: 6402314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
    Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
    J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical observations of the Ledakrin effects in treatment of patients with malignant neoplasms.
    Piotrowska-Sowińska J
    Mater Med Pol; 1976; 8(3):266-72. PubMed ID: 1011868
    [No Abstract]   [Full Text] [Related]  

  • 11. Preliminary observations on the Ledakrin effects in treatment of patients with lung carcinoma.
    Kwasniewska-Rokicińska C; Swiecki J; Drosik K
    Mater Med Pol; 1976; 8(3):289-94. PubMed ID: 1011871
    [No Abstract]   [Full Text] [Related]  

  • 12. [Distribution and metabolism of a with C-14 labeled cytostatic drug in the organisms].
    Jászsági-Nagy E; Elekes I
    Strahlentherapie; 1968 Jun; 135(6):688-92. PubMed ID: 5682133
    [No Abstract]   [Full Text] [Related]  

  • 13. Absorption, tissue distribution, and excretion of the anti-neoplastic agent guanazole in the rat.
    Musa MN; Lower GM; Welling PG; Johnson BM; Kaiman BD; Bryan GT
    Res Commun Chem Pathol Pharmacol; 1974 Mar; 7(3):497-512. PubMed ID: 4824824
    [No Abstract]   [Full Text] [Related]  

  • 14. Ledakrin--anticancerous medicine 1-nitro-9(3-dimethylaminopropylamino)-acridine -2HCl-H2O.
    Ledochowski A
    Mater Med Pol; 1976; 8(3):237-51. PubMed ID: 796591
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of Ledakrin on renal and hepatic functions.
    Bratkowska-Seniów B; Kaniak T; Stumpf A; Wahl-Mugeńska M; Wojnarska J
    Mater Med Pol; 1976; 8(3):316-22. PubMed ID: 1011874
    [No Abstract]   [Full Text] [Related]  

  • 16. Results of combined treatment withlung tissue resection and simultaneous administration of Ledakrin in bronchial carcinoma.
    Rogalski E; Domagala J; Kolodziej J
    Mater Med Pol; 1976; 8(3):311-5. PubMed ID: 1011873
    [No Abstract]   [Full Text] [Related]  

  • 17. Behavior of some biochemical components of blood of patients with ovarian carcinoma during Ledakrin treatment.
    Dobryszcka W
    Mater Med Pol; 1976; 8(3):302-10. PubMed ID: 1034859
    [No Abstract]   [Full Text] [Related]  

  • 18. Ledakrin - a new polish antitumor drug.
    Radzikowski C
    Mater Med Pol; 1976; 8(1):56-7. PubMed ID: 1263586
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacological studies on dimetacrine. I. Studies on the absorption, distribution and excretion of H3-labeled dimetacrine in the rat.
    Ishitani R; Saito E; Kitagawa H
    Jpn J Pharmacol; 1970 Sep; 20(3):432-8. PubMed ID: 5312397
    [No Abstract]   [Full Text] [Related]  

  • 20. Morphologic blood pattern in patients treated with Ledakrin.
    Bratkowska-Seniów B; Dziedzic J; Fengler I; Steuden W; Szymaniec S; Wysocka M
    Mater Med Pol; 1976; 8(3):295-301. PubMed ID: 1011872
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.